LAGUNA HILLS, Calif. , August 2, 2021 – (BUSINESS WIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCBD) (PharmaCyte or Company), a biotechnology company focused on the emergence of mobile treatments for cancer and diabetes, is live The exclusive Cell encapsulation technology, Cell-in-a-Box®, today announced that The Nasdaq Stock Market LLC (Nasdaq) has approved the board of the Company’s non-unusual shares on Nasdaq. symbol “PMCB” . PharmaCyte also announced its goal to offer and sell, depending on the market and other conditions, non-unusual shares (or pre-financed warrants to acquire non-unusual shares instead of unusual shares) and warrants to acquire non-unusual shares in a public offering.
With respect to the proposed public offering, the Company intends to grant the insurer a 30-day option to acquire more shares of its non-unusual shares and/or warrants to acquire shares of its non-unusual shares at the public offering price. , less subscription refunds and commissions. All securities for sale under the offering will be offered through PharmaCyte.
H. C. Wainwright acts as the exclusive administrator of the proposed offer.
The Company’s non-unusual shares will continue to be traded on the OTC Markets directory formula at the OTCQB Venture market venue until the commencement of trading on the Nasdaq, which the Company expects to have following the price of the proposed public offering. , however, it is a matter of market and other situations, and there is no guarantee that or when the offer will possibly be made, nor as to the actual duration or situations of the offer be.
PharmaCyte intends to use the net proceeds from this provision to carry out activities requested through the U. S. Food and Drug Administration. U. S. (FDA) to address FDA’s clinical suspension of its New Drug Research (IND) application regarding Phase 2b Clinical Trial in The Allocation of Locally Advanced and Inoperable Pancreatic Cancer (LAPC) Matrix that adds the finishing touch of several additional preclinical studies and tests and the provision to the FDA of the additional data it has requested , (ii) to begin the investment and achieve the Phase 2b clinical trial in LAPC, provided that the clinical suspension of the IND is lifted, and (iii) for general working capital purposes.
The values described above are submitted through PharmaCyte in accordance with a Statement of Registration on Form S-3 (File No. 333-255044) which was filed in the past with the Securities and Exchange Commission (SEC) and declared effective on April 14, 2021. Possibly, the securities would only be presented through a prospectus, adding a supplementary prospectus, which is part of the effective registration statement. on the SEC’s online page at www. sec. gov. Electronic copies of the initial prospectus supplement and the accompanying base prospectus in connection with the offer, where available, would possibly also be received by contacting HCWainwright
This press release shall constitute an offer to sell or the solicitation of an offer to purchase the securities of such offer, nor shall there be a sale of such securities in any state or other jurisdiction in which it is offered. , the solicitation or sale would be illegal. prior to registration or qualification under the securities laws of that state or other jurisdiction. Any offer, if any, will be made only through the prospectus supplement and the training component of the package leaflet attached to the registration statement.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. es a biogeneration company developing mobile treatments for cancer and diabetes in a proprietary mobile encapsulation generation living in mobileulose known as “Cell-in-a-Box®. This generation is used as a platform in which treatments for various types of cancer and diabetes develop.
PharmaCyte’s cancer product candidate is to encapsulate genetically modified human cells that convert an inactive chemotherapy drug into its active or “anticancer” form. For pancreatic cancer, these encapsulated cells are implanted in the blood source of the patient’s tumor as close as you can imagine Once implanted, the ifosfamide chemotherapy prodrug that is usually activated in the liver is given intravenously at one-third of the overall dose. Ifosfamide passes through the pores of the capsules, the living internal cells act as a “bio-artificial liver” and activate the ifosfamide chemotherapy prodrug at the cancer site.
PharmaCyte’s product candidate for type 1 diabetes and insulin-dependent type 2 diabetes is to encapsulate a line of human liver cells genetically modified to produce and release insulin in reaction to blood sugar levels in the human body. stem cells to treat diabetes. The encapsulation of the cell line will be carried out with Cell-in-a-Box technology®. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will serve as a “bio-artificial pancreas” for insulin production.
Safe Harbor
This press release would possibly involve forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 which makes explicit the existing ideals and expectations of control of PharmaCyte. All statements involved in this press release that do not describe old facts are forward-looking statements that are subject to dangers and uncertainties that may also cause actual effects, functionality, and achievements to differ materially from those discussed in those forward-looking statements. The parent’s forward-looking statements come with those relating to the proposed public that will provide the PharmaCyte securities, adding with respect to the final touch of the proposed public that it provides described above, the option that the Common Stock would possibly begin trading on the Nasdaq, the intended use of the product, the prospective terms of supply and PharmaCyte’s expectations related to granting the insurer a 30-day option to acquire more securities, all of which would possibly be overcome, among other things, delays in assembly o non-compliance with end situations similar to the proposed audience being provided and unfa vorable adjustments in general market and economic situations. Factors that may also simply our actual effects come from our ability to list our non-unusual inventories in a national inventory bag and then maintain that list, raise the capital requirement to fund our operations, and locate partners to supplement our functions and resources, respond successfully to Issues raised through the US Food and Drug Administration to remove the clinical suspension of our IND so that we can continue our planned clinical trial for locally complex and inoperable pancreatic cancer, as well as other issues that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the United States Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we do not assume any legal responsibility to update or revise any forward-looking statements, unless otherwise required by law, either as a result of new information. run occasions or in a different way.
You can learn more about PharmaCyte Biotech at www. PharmaCyte. com. You may also receive information by contacting PharmaCyte’s Investor Relations Department.
See the businesswire. com edition: https://www. businesswire. com/news/home/20210802005764/en/
contacts
Dr. Gerald W. Crabtree Investor Relations: PharmaCyte Biotech, Inc. Investor Relations Department Phone: 917. 595. 2856 Email: InvestorRelations@PharmaCyte. com